A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease (RILIEF)

Sanofi

Status and phase: Enrolling; Phase 3

Conditions: Immunoglobulin G4 Related Disease

Treatments: Drug: Rilzabrutinib; Drug: Placebo; Drug: Glucocorticoid

Study type: Interventional

Funder types: Industry

Identifiers

NCT07190196

2025-521398-15 (Registry Identifier)

U1111-1316-0266 (Registry Identifier)

EFC17359

Details and patient eligibility

About

This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.

The purpose of this study is to measure time to IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period.

Study details include:

The study duration will be up to 60 weeks, including a 4 to 6-week screening period, a 52-week double blind treatment period, and 2 weeks of follow up (plus an optional OLE of 108 weeks).

The number of visits will be 16 (plus an optional 9 visits during the OLE).

Enrollment: 124 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must have an adjudicated clinical diagnosis of IgG4-RD
• Participants meeting Step 1 Entry criteria of 2019 ACR/EULAR classification criteria for IgG4-RD and Total inclusion points are ≥20
• Participants with active disease at screening in at least one organ system, excluding lymph nodes, as an IgG4-RD Responder Index total activity score ≥ 2
• Participants with history or current involvement of at least 1 organ/site (excluding lymph nodes) affected with IgG4-RD.
• Participants with active IgG4-RD controlled for at least 2 weeks while on a stable dose of GC.
• Participants willing to taper off GC after starting IMP.
• Participants willing and able to participate in repeated study protocol mandated or clinically indicated imaging procedures to assess IgG4-RD such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), or ultrasound.
• Participants who have an up-to-date vaccination status as per local guidelines. The last dose of live vaccines should be received at least 30 days before Day 1.
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

• Meet any Step 2 Exclusion criteria from the 2019 ACR/EULAR classification criteria for IgG4-RD.
• History of retroperitoneal fibrosis, sclerosing mesenteritis, fibrosing mediastinitis, or other overwhelmingly fibrotic expression of IgG4-RD that is the sole disease manifestation.
• Active malignancy or history of malignancy within 5 years before Day 1, except completely treated in situ carcinoma of the cervix, completely treated, and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
• Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
• History of serious infections with the potential for recurrence (as judged by the Investigator), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher).
• Current or chronic history of liver disease unrelated to IgG4-RD.
• Refractory nausea and vomiting, malabsorption, external biliary shunt, bariatric surgery, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption.
• History of solid organ transplant.
• Planned major surgical procedure during the participation in this study.
• History of drug abuse within the previous 12 months.
• Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day.
• Prior participation in any rilzabrutinib studies or other BTK inhibitor studies.
• History of treatment with an investigational drug within 6 months or 5 half-lives of the investigational drug, whichever is longer.
• Laboratory abnormalities at the screening visit identified by the central laboratory The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

124 participants in 2 patient groups, including a placebo group

Rilzabrutinib

Experimental group

Description:

Rilzabrutinib

Treatment:

Drug: Glucocorticoid

Drug: Rilzabrutinib

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Glucocorticoid

Drug: Placebo